Bharat Biotech has announced that it has enrolled 25,800 volunteers for phase 3 clinical trials of its COVID-19 vaccine, Covaxin, thereby concluding the requirement process. "My deep appreciation to all the volunteers for reposing trust and expressing pro-vaccine public health volunteerism in... India's first fully indigenous COVID-19 vaccine," Bharat Biotech 's Joint Managing Director said.
Requirement process was extended by a week.
Comments
Post a Comment